Close

GlycoMimetics (GLYC) Commences Dosing of GMI-1271 Phase 2 in AML

June 6, 2016 9:05 AM EDT Send to a Friend
GlycoMimetics, Inc. (Nasdaq: GLYC) announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login